Oncternal Says First Patient Dosed In Phase 1/2 Study Of ROR1 Targeting Autologous CAR T, ONCT-808, In Patients With Relapsed Or Refractory Aggressive B-Cell Lymphoma
Portfolio Pulse from Benzinga Newsdesk
Oncternal Therapeutics has dosed the first patient in a Phase 1/2 study of ONCT-808, a ROR1 targeting autologous CAR T cell therapy for relapsed or refractory aggressive B-cell lymphoma. Initial clinical data is expected in late 2023, with additional readouts in 2024.
June 06, 2023 | 8:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oncternal Therapeutics has initiated a Phase 1/2 study of ONCT-808, a ROR1 targeting CAR T therapy for aggressive B-cell lymphoma, with initial data expected in late 2023.
The initiation of the Phase 1/2 study for ONCT-808 is a positive development for Oncternal Therapeutics, as it represents progress in their pipeline. If the trial yields positive results, it could lead to increased investor interest and potential growth in the company's stock price. However, the impact may be limited in the short term, as initial data is not expected until late 2023.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100